US Bancorp
SPRO icon

US Bancorp’s Spero Therapeutics SPRO Stock Holding History

US Bancorp’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$353 Hold
151
– – ﹤0.01% 4036
2025
Q4 		$352 Hold
151
– – ﹤0.01% 3946
2025
Q3 		$284 Hold
151
– – ﹤0.01% 3911
2025
Q2 		$438 Hold
151
– – ﹤0.01% 4020
2025
Q1 		$109 Sell
151
-5,000
-97% -$4.22K ﹤0.01% 4137
2024
Q4 		$5.31K Buy
5,151
+5,000
+3,311% +$5.95K ﹤0.01% 3636
2024
Q3 		$202 Hold
151
– – ﹤0.01% 4014
2024
Q2 		$196 Hold
151
– – ﹤0.01% 3909
2024
Q1 		$260 Hold
151
– – ﹤0.01% 3902
2023
Q4 		$222 Hold
151
– – ﹤0.01% 3903
2023
Q3 		$183 Hold
151
– – ﹤0.01% 3915
2023
Q2 		$219 Hold
151
– – ﹤0.01% 3920
2023
Q1 		$219 Hold
151
– – ﹤0.01% 4015
2022
Q4 		$261 Hold
151
– – ﹤0.01% 4048
2022
Q3 		$0 Hold
151
– – ﹤0.01% 4209
2022
Q2 		$0 Sell
151
-1,000
-87% -$2.91K ﹤0.01% 4218
2022
Q1 		$10K Hold
1,151
– – ﹤0.01% 3381
2021
Q4 		$18K Buy
1,151
+151
+15% +$2.4K ﹤0.01% 3170
2021
Q3 		$18K Sell
1,000
-2,000
-67% -$32.1K ﹤0.01% 3188
2021
Q2 		$42K Hold
3,000
– – ﹤0.01% 2762
2021
Q1 		$44K Hold
3,000
– – ﹤0.01% 2643
2020
Q4 		$58K Hold
3,000
– – ﹤0.01% 2456
2020
Q3 		$33K Buy
3,000
+2,000
+200% +$23.7K ﹤0.01% 2585
2020
Q2 		$14K Buy
1,000
+500
+100% +$5.61K ﹤0.01% 2982
2020
Q1 		$4K Hold
500
– – ﹤0.01% 3334
2019
Q4 		$5K Hold
500
– – ﹤0.01% 3285
2019
Q3 		$5K Buy
+500
New +$5.27K ﹤0.01% 3253

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

US Bancorp's SPRO Position: Q1 2026 in Review

US Bancorp held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 151 shares worth $353. The position accounts for ﹤0.01% of the portfolio, ranked #4036.

US Bancorp first reported a position in SPRO in Q3 2019 and has held it in 27 quarters since. The position peaked at $58K in Q4 2020. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • US Bancorp held 151 shares of Spero Therapeutics worth $353 as of Q1 2026.
  • US Bancorp left its Spero Therapeutics share count unchanged in Q1 2026.
  • Spero Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4036 holding.
  • US Bancorp first reported a position in Spero Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • US Bancorp's Spero Therapeutics position peaked at $58K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.